Skip to main content
SINSIN PHARMACEUTICAL Co., LTD. logo

SINSIN PHARMACEUTICAL Co., LTD. — Investor Relations & Filings

Ticker · 002800 ISIN · KR7002800001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2022-03-07 AGM Information
Country KR South Korea
Listing KO 002800

About SINSIN PHARMACEUTICAL Co., LTD.

https://sinsin2002.tradekorea.com/

Sinsin Pharmaceutical Co., Ltd. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of over-the-counter (OTC) medicines for external use. The company's core product portfolio centers on topical anti-inflammatory and analgesic drugs, including its widely recognized brand of pain relief patches, "SINSIN PAS," alongside various sprays and lotions. The company also produces a diverse range of consumer healthcare items such as mosquito repellents, wound care products like surgical plasters and healing bands, anti-mycotic treatments, and other dermatological preparations for both domestic and overseas markets.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Sinsin Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities and financial statements (balance sheets and income statements) for the 59th fiscal year. While it contains financial data, it is specifically a proxy statement/notice for an upcoming shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement). It provides shareholders with information regarding the upcoming Annual General Meeting (AGM), including agenda items, voting procedures, and financial summaries to assist in the proxy voting process. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-07 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Shinshin Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2022-02-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This is a standard regulatory filing used to disclose insider trading activities (purchases/sales of company shares by directors or major shareholders). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-02-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Shinshin Pharmaceutical) disclosing a significant change in revenue or profit structure (30% or more). This is a standard regulatory disclosure requirement in Korea for listed companies to report preliminary financial results before the final audit is completed. Since it provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change, it fits the definition of an Earnings Release (ER). FY 2021
2022-02-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) used to disclose insider trading or changes in share ownership by company directors or major shareholders. Based on the provided categories, this fits the 'Director's Dealing' (DIRS) classification, which covers personal share transactions by company directors and executives.
2022-01-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.